J&J’s Darzalex shows promise in newly-diagnosed multiple myeloma

13th December 2017 Uncategorised 0

Johnson & Johnson group Janssen has unveiled new data showing a 50 percent cut in the risk of disease progression or death in patients with newly diagnosed multiple myeloma given Darzalex on top of standard treatment.

More: J&J’s Darzalex shows promise in newly-diagnosed multiple myeloma
Source: News